You are here

gene therapy

4DMT shoots for a $75M IPO, its second attempt to go public with its gene therapy vector programs

4DMT shoots for a $75M IPO, its second attempt to go public with its gene therapy vector programs

Endpoints

4D Molecular Therapeutics

Flag link:

Bayer powers gene-editing startup Metagenomi to $65M A round

Bayer powers gene-editing startup Metagenomi to $65M A round

Fierce Biotech

Flag link:

UCB accelerates ambitions in gene therapy with two deals

UCB accelerates ambitions in gene therapy with two deals

Pharma Letter

Handl Therapeutics

Lacerta Therapeutics

Flag link:

Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands

Axovant Changes Name to Sio Gene Therapies, Adding to List of Biopharma Company Rebrands

BioSpace

Sio Gene Therapies

Flag link:

Pfizer invests in Homology and adds to its gene therapy ambitions

Pfizer invests in Homology and adds to its gene therapy ambitions

BioPharma Dive

Homology Medicines

Flag link:

Decibel Therapeutics raises $82M as Laurence Reid looks to steer gene therapy pivot

Decibel Therapeutics raises $82M as Laurence Reid looks to steer gene therapy pivot

Endpoints

Decibel Therapeutics

Flag link:

FDA gene therapy holdups suggest closer scrutiny by agency

FDA gene therapy holdups suggest closer scrutiny by agency

BioPharma Dive

Sarepta Therapeutics

Voyager Therapeutics

Flag link:

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

FDA scuttles bluebird's accelerated plans for sickle cell gene therapy, as higher CMC bar forces 1-year delay

Endpoints

sickle cell disease

Flag link:

Catalent continues big push into cell and gene therapies with Belgian facility buyout

Catalent continues big push into cell and gene therapies with Belgian facility buyout

Fierce Pharma

Flag link:

Novartis sharpens focus on vision-restoring gene therapy with $150M Vedere buyout

Novartis sharpens focus on vision-restoring gene therapy with $150M Vedere buyout

Fierce Biotech

Flag link:

Bayer to buy AskBio for $2B in bid to become a gene therapy player

Bayer to buy AskBio for $2B in bid to become a gene therapy player

BioPharma Dive

Flag link:

Disruptor in cell and gene therapy space secures US$30m in funding

Disruptor in cell and gene therapy space secures US$30m in funding

Biopharma Reporter

Flag link:

Pfizer: Expanding North Carolina Gene Therapy Facility and Adding Jobs

Pfizer: Expanding North Carolina Gene Therapy Facility and Adding Jobs

BioSpace

drug manufacturing

Flag link:

FDA officials, experts discuss impact of Covid-19 on cell and gene therapies

FDA officials, experts discuss impact of Covid-19 on cell and gene therapies

Endpoints

Flag link:

Sarepta partner Lysogene reports patient death in AAVance clinical trial

Sarepta partner Lysogene reports patient death in AAVance clinical trial

The Fly

Sarepta Therapeutics

clinical trials

Flag link:

Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B

Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B

Fierce Biotech

Spark Therapeutics

Flag link:

Voyager Takes a Hit After FDA Places Hold on Gene Therapy for Huntington's Disease

Voyager Takes a Hit After FDA Places Hold on Gene Therapy for Huntington's Disease

BioSpace

Voyager Therapeutics

Huntington's disease

Flag link:

Fujifilm expands its gene therapy drug CDMO business

Fujifilm expands its gene therapy drug CDMO business

Biopharma Reporter

Flag link:

FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial

FDA Lifts Clinical Hold on Solid Biosciences’ DMD Gene Therapy Trial

BioSpace

Solid Biosciences

clinical trials

Duchenne Muscular Dystrophy

Flag link:

CPhl event to draw attention to M&A activity in gene and cell sector

CPhl event to draw attention to M&A activity in gene and cell sector

Biopharma Reporter

Flag link:

Pages